These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 9498941)

  • 1. Proventil HFA and ventolin have similar safety profiles during regular use.
    Tinkelman DG; Bleecker ER; Ramsdell J; Ekholm BP; Klinger NM; Colice GL; Slade HB
    Chest; 1998 Feb; 113(2):290-6. PubMed ID: 9498941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics.
    Bleecker ER; Tinkelman DG; Ramsdell J; Ekholm BP; Klinger NM; Colice GL; Slade HB
    Chest; 1998 Feb; 113(2):283-9. PubMed ID: 9498940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin.
    Dockhorn RJ; Wagner DE; Burgess GL; Hafner KB; Letourneau K; Colice GL; Klinger NM
    Ann Allergy Asthma Immunol; 1997 Jul; 79(1):85-8. PubMed ID: 9236507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma.
    Lumry W; Noveck R; Weinstein S; Barnhart F; Vandermeer A; Murray A; Reisner C
    Ann Allergy Asthma Immunol; 2001 Mar; 86(3):297-303. PubMed ID: 11289328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma.
    Shapiro GS; Klinger NM; Ekholm BP; Colice GL
    J Asthma; 2000 Dec; 37(8):667-75. PubMed ID: 11192231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of long-term treatment with HFA albuterol.
    Ramsdell JW; Klinger NM; Ekholm BP; Colice GL
    Chest; 1999 Apr; 115(4):945-51. PubMed ID: 10208190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma.
    Shapiro G; Bronsky E; Murray A; Barnhart F; VanderMeer A; Reisner C
    Arch Pediatr Adolesc Med; 2000 Dec; 154(12):1219-25. PubMed ID: 11115306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients.
    Langley SJ; Sykes AP; Batty EP; Masterson CM; Woodcock A
    Ann Allergy Asthma Immunol; 2002 May; 88(5):488-93. PubMed ID: 12027070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. German Study Group.
    Baumgarten CR; Dorow P; Weber HH; Gebhardt R; Kettner J; Sykes AP
    Respir Med; 2000 Jun; 94 Suppl B():S17-21. PubMed ID: 10919681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Equivalence of salbutamol 200 microg four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Eastern European study group.
    Salat D; Popov D; Sykes AP
    Respir Med; 2000 Jun; 94 Suppl B():S22-8. PubMed ID: 10919682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Azmacort HFA Study Group.
    Welch M; Bernstein D; Gross G; Kane RE; Banerji D
    Chest; 1999 Nov; 116(5):1304-12. PubMed ID: 10559092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects.
    Tripp K; McVicar WK; Nair P; Corren J; Pleskow WW; Goodwin E; Baumgartner RA; Hanrahan JP
    J Allergy Clin Immunol; 2008 Sep; 122(3):544-9. PubMed ID: 18692886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of Aerosol Hydrofluoroalkane HFA-134a Elimination in the Exhaled Human Breath Following Inhaled Corticosteroids Administration.
    Shin HW; Barletta B; Yoonessi L; Meinardi S; Leu SY; Radom-Aizik S; Randhawa I; Nussbaum E; Blake DR; Cooper DM
    Clin Transl Sci; 2015 Oct; 8(5):445-50. PubMed ID: 26155923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.
    FitzGerald JM; Chapman KR; Della Cioppa G; Stubbing D; Fairbarn MS; Till MD; Brambilla R
    J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):427-35. PubMed ID: 10069876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol.
    Bronsky E; Ekholm BP; Klinger NM; Colice GL
    J Asthma; 1999; 36(1):107-14. PubMed ID: 10077140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group.
    Ayres JG; Millar AB; Sykes AP
    Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose.
    Davies RJ; Stampone P; O'Connor BJ
    Respir Med; 1998 Jun; 92 Suppl A():23-31. PubMed ID: 9850360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.